Platinum‐combination chemotherapy with or without immune‐checkpoint inhibitor in patients with postoperative recurrent non‐small cell lung cancer previously treated with adjuvant platinum‐doublet chemotherapy: A multicenter retrospective study

Platinum‐combination chemotherapy with or without immune‐checkpoint inhibitor in patients with postoperative recurrent non‐small cell lung cancer previously treated with adjuvant platinum‐doublet chemotherapy: A multicenter retrospective study

Abstract Background Rechallenge with platinum‐combination chemotherapy in patients with advanced non‐small cell lung cancer (NSCLC) after disease progression on platinum‐combination chemotherapy occasionally leads to a favorable response. The efficacy and safety of platinum‐combination chemotherapy...

Full description

Bibliographic Details
Main Authors: Kakeru Hisakane, Takehiro Tozuka, Satoshi Takahashi, Namiko Taniuchi, Nobuhiko Nishijima, Kenichiro Atsumi, Tetsuya Okano, Masahiro Seike, Takashi Hirose
Format: Article
Language:English
Published: Wiley 2023-07-01
Series:Thoracic Cancer
Subjects:
immune‐checkpoint inhibitor
non‐small cell lung cancer
platinum‐combination chemotherapy
postoperative recurrence
Online Access:https://doi.org/10.1111/1759-7714.14992

Similar Items

Similar Items